Clearance of theFullFocushigh-performance viewer opens the market to increased interoperability so pathologists can digitally diagnose cases with fewer IT barriers.

Company’s continued product portfolio of innovation in telepathology and digital diagnostics accelerated by further investment.

The Paige Platform and FullFocus Viewer were used in this research study.

In a research investigation, Paige Prostate Clinical (CE-IVD) was shown to improve pathologists' sensitivity when reviewing digitized H&E prostate needle biopsy images with a minor impact on specificity. The results, which showed Paige Prostate Clinical's (CE-IVD) slide-level sensitivity was 98.9% and its specificity was 93.3% were published by ASCO20.

Dr. Matthew Hanna, Director of Digital Pathology Informatics at Memorial Sloan Cancer Center took on the task of validating a digital pathology system including remote review during the COVID-19 pandemic and showed high (100%) intraobserver digital to glass slide major diagnostic concordance when reporting from a remote site. This randomized, prospective study successfully validated remote use of a digital pathology system including operational feasibility supporting remote review and reporting of pathology specimens, and evaluation of remote access performance and usability for remote sign out.

Our study in Modern Pathology showed how Paige Prostate alpha version helped pathologists overcome this challenge. 

Company continues to accelerate international adoption while strengthening its leadership position as the first clinical-grade AI in pathology.

Company continues to accelerate international adoption while strengthening its leadership position as the first clinical-grade AI in pathology.

Chavez joins Paige’s board after recently retiring from Goldman Sachs, where he served 19 years in multiple roles —including CIO, CFO, and Co-Head of Securities. He’s been credited as one of the key figures in elevating the roles of engineering and data science, both at Goldman Sachs and in the financial services sector more broadly. In this hands-on role at Paige, he will be working with the Company to help create a similar transformation in healthcare.

Paige, the leader in computational pathology transforming the diagnosis and treatment of cancer, today announced it has closed its Series B funding round of $45 million, bringing the Company’s total capital raised to over $70 million. Paige will use this new capital to drive FDA clearance of its products and expand its portfolio, delving deeper into cancer pathology, novel biomarkers, and prognostic capabilities.

Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Paige, a leader in computational pathology, announced today a strategic collaboration to deliver clinical-grade AI applications to pathology laboratories. These AI technologies, starting with Paige Prostate, aim to help pathologists identify, quantify, and characterize cancer in tissue samples and make precise diagnoses more efficiently. This may, ultimately, positively impact pathologists’ workflow and treatment planning for patients.

Paige has achieved CE mark for two products: Paige Prostate, a clinical-grade AI solution for cancer detection in prostate needle biopsies, and Insight, our AI-native viewer that primary diagnosis that pathologists can use to perform diagnosis on images, supported by AI results across their workflow.

In addition to listing Paige as one of their most promising startups, CB Insights highlights Paige as one of the leaders in the transformation of pathology through artificial intelligence.

Article Published in Nature Medicine Provides Further Scientific Evidence for Deployment of Computational Decision Support Systems to Improve Patient Care.

With the help of NVIDIA technology, Paige.AIis able totrain deep neural networks from hundreds of thousands of gigapixel images of whole slides.

Revolutionizing cancer diagnostics through computational power — exploring the ultimate ambitions of the Pathology Artificial Intelligence Guidance Engine.

Expedites Product Development and Provides Priority Regulatory Review For Paige.AI’s pioneering Clinical-Grade Artificial Intelligence in Pathology.

Dr. Leo Grady is a seasoned healthcare technology leader with more than 15 years of experience in prototyping, developing, and bringing to market some of the industry’s most advanced machine learning, computer vision, and medical imaging technologies and products.

The conference is where the latest information is presented by leading researchers in image processing, physics, computer-aided diagnosis, perception, image-guided procedures, biomedical applications, ultrasound, informatics, radiology, and digital pathology.

Over the last several years, the pharmaceutical and healthcare organizations have developed a strong interest toward applying artificial intelligence (AI) in various areas, ranging from medical image analysis and elaboration of electronic health records (EHRs) to more basic research like building disease ontologies, preclinical drug discovery, and clinical trials. The demand for the ML/AI technologies, as well as for ML/AI talent, is growing in the pharmaceutical and healthcare industries and driving the formation of a new interdisciplinary industry (‘data-driven healthcare’).

The CB Insights research team selected the 100 startups from a pool of 3K+ companies based on several factors, including patent activity, investor profile, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty.

Through its partnership with Igneous, Paige.AI will be able to securely and efficiently manage eight petabytes (PB) of unstructured data as part of an integrated machine learning-based healthcare AI workflow.

Thomas Fuchs of Paige.AI wins the Crain’s New York Heritage Research Investigators in Translational Medicine Award. Our team is humbled and inspired by this recognition!

The Warren Alpert Center for Digital and Computational Pathology at MSKCC was established in 2017 as an innovation center to facilitate novel research and development in digital pathology and computational pathology for clinical cancer care and research. Paige.AI’s founder Thomas Fuchs serves as center director for Computational Pathology.

Science produced a beautiful video explaining the inner workings of deep neural networks and how to open the black box, based on a paper by JasonYosinskiand our CSO Thomas Fuchs.

Paige.AI’s founder gave an interview about the challenges of AI in medicine in general and in Computational Pathology in particular.

Paige.AI’s founder, Thomas Fuchs, was invited to speak at NVIDIA’s GTC AI in Healthcare Summit.